Missale, G.

patient response treatment genotype steatosi t-cell hepatitis hepatitis c study decline therapy signi phase kinetic hcv-speci virus baseline allele ficant frequency hla-a peptide analysis model ribavirin outcome fi rst month group value t-cell lines hepatitis c virus liver il 28b polymorphisms effect t-cell response hla-a 2 non-rvr proliferative t-cell responses expansion signi ficantly infection result hepatology level signi ficant fi rst phase journal hepatology 2011 vol treatment outcome polymorphism proliferative figure brosi –liver pancreas tetramer association il 28b body mass index genotype 3 interferon ficantly hcv rna hcv infection rvr patients 0.5 fi brosis stage non-rvr patients table hcv rna decline rs 12979860 liver steatosis ifn -␥ production point cd 8 analysis non-svr slope cytotoxic carrier 0.1 phase decline